6noINTRODUCTION: Intravenous thrombolysis within 4.5 hours from symptom onset improves functional outcome in acute ischemic stroke patients. Repeated intravenous tissue plasminogen activator (IVtPA) is contraindicated in patients presenting with early recurrent stroke (ERS) within 3 months from the initial stroke because of a greater risk of intracranial hemorrhage. CASE PRESENTATION: A 59-year-old man presented with ERS, National Institute of Health Stroke Scale of 16, 10 days after a previous stroke. Brain computed tomography (CT) showed a previous hypodensity with 4 cm volume. Angio-CT highlighted the left middle cerebral artery and left internal carotid occlusion. Perfusion CT showed small deep core and large penumbra. The patient ...
Intravenous (IV) thrombolysis is a safe and effective treatment for acute ischemic stroke. The thera...
Background: The administration of tissue plasminogen activator (t-PA) has been proven effective for ...
Background. Recurrent ischemic stroke is associated with adverse neurological outcome in patients wi...
Intravenous thrombolysis (IVT) within 4.5 hours from symptom onset improves functional outcome in pa...
BACKGROUND: We assessed the incidence of early recurrent ischemic stroke in stroke patients treated ...
Background and Purpose—Mechanisms of early neurologic deterioration after treatment with intravenous...
Background Acute ischemic stroke (AIS) has a high risk of recurrence, particularly in the early stag...
Background: Current guidelines recommend withholding antithrombotic therapy (ATT) for at least 24 h ...
Acute ischemic vertebrobasilar stroke (AIVBS) is usually associated with poor outcome and prognosis ...
<p><b>Background and Purpose:</b> Mechanisms of early neurologic deterioration aft...
<b><i>Objective:</i></b> Increased use of systemic thrombolysis, demographic changes, and higher cha...
BACKGROUND: Current guidelines recommend withholding antithrombotic therapy (ATT) for at least 24 h ...
Background The likelihood of severe disability and death increases with each recurrent stroke. Repe...
Intravenous (IV) thrombolysis is a safe and effective treatment for acute ischemic stroke. The thera...
Background. Patients with acute ischemic stroke due to internal carotid artery (ICA) disease are at ...
Intravenous (IV) thrombolysis is a safe and effective treatment for acute ischemic stroke. The thera...
Background: The administration of tissue plasminogen activator (t-PA) has been proven effective for ...
Background. Recurrent ischemic stroke is associated with adverse neurological outcome in patients wi...
Intravenous thrombolysis (IVT) within 4.5 hours from symptom onset improves functional outcome in pa...
BACKGROUND: We assessed the incidence of early recurrent ischemic stroke in stroke patients treated ...
Background and Purpose—Mechanisms of early neurologic deterioration after treatment with intravenous...
Background Acute ischemic stroke (AIS) has a high risk of recurrence, particularly in the early stag...
Background: Current guidelines recommend withholding antithrombotic therapy (ATT) for at least 24 h ...
Acute ischemic vertebrobasilar stroke (AIVBS) is usually associated with poor outcome and prognosis ...
<p><b>Background and Purpose:</b> Mechanisms of early neurologic deterioration aft...
<b><i>Objective:</i></b> Increased use of systemic thrombolysis, demographic changes, and higher cha...
BACKGROUND: Current guidelines recommend withholding antithrombotic therapy (ATT) for at least 24 h ...
Background The likelihood of severe disability and death increases with each recurrent stroke. Repe...
Intravenous (IV) thrombolysis is a safe and effective treatment for acute ischemic stroke. The thera...
Background. Patients with acute ischemic stroke due to internal carotid artery (ICA) disease are at ...
Intravenous (IV) thrombolysis is a safe and effective treatment for acute ischemic stroke. The thera...
Background: The administration of tissue plasminogen activator (t-PA) has been proven effective for ...
Background. Recurrent ischemic stroke is associated with adverse neurological outcome in patients wi...